ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Blood-Brain Barrier-Penetrant Ag(III) Corrole Compound Rescues Alzheimer's Disease Pathology by Targeting Aβ42-Induced Oxidative Stress.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Covalent Resveratrol-Polyoxometalate Hybrid for Synergistic Disassembly of Prion Protein Fragment 106-126 Aggregates and Catalytic Scavenging of Reactive Oxygen Species.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A Blood-Brain Barrier-Penetrant Ag(III) Corrole Compound Rescues Alzheimer's Disease Pathology by Targeting Aβ42-Induced Oxidative Stress.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alzheimer's disease (AD) lacks disease-modifying therapies, partly due to the blood-brain barrier (BBB) limiting drug delivery and the multifaceted toxicity of amyloid-β (Aβ42) oligomers. Here, this work reports the design, synthesis, and comprehensive characterization of a rationally designed silver(III) corrole complex, (Mor-Cor)Ag(III) featuring a morpholino substituent at the periphery of the macrocycle, engineered to overcome these challenges through: (1) a morpholino moiety enabling BBB penetration (validated by mass spectrometry and fluorescence imaging), and (2) a redox-active Ag(III) center that scavenges Aβ42-induced reactive oxygen species (ROS). Detailed structural, spectroscopic, and density functional theory (DFT) analyses are performed to elucidate the electronic features of the complex. Further through multimodal biological validation in in vitro and in vivo transgenic AD models, (Mor-Cor)Ag(III) is shown to disrupt Aβ42 aggregation and decrease ROS levels leading to decrease in dystrophic neurites, neuronal hyperactivity and neuronal death. (Mor-Cor)Ag(III) significantly outperformed its unsubstituted analog, (Cor)Ag(III) in its ability to provide neuroprotection. This work establishes morpholine-appended metallocorroles as a new class of neuroprotective drugs to address unmet therapeutic needs in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.